Anja Harmeier has taken over from her previous boss to head the pharma group’s CVC.
Anja Harmeier has returned to pharmaceutical company Roche’s startup investment arm to lead the team following the retirement of former corporate venturing head Carole Nuechterlein.
She was previously on Roche Venture Fund’s investment team between 2016 and 2020, and has also held roles in neuroscience and rare disease research at the parent company.
More recently, she was CEO of remyelination technology developer Rewind Therapeutics for the past four and a half-years. Before that, she spent a year-and-a-half as partner at venture capital firm BB Pureos Bioventures.
“It is an honour to succeed Carole Nuechterlein – my former boss who taught me the ropes when I started out in venture capital,” said Harmeier on LinkedIn.
“Even though her shoes are large to fill, I am excited about this opportunity to build on her incredible legacy.”
Roche Venture Fund is a CHF 750m ($940m) evergreen fund focusing on pharmaceuticals, diagnostic and digital health startups. Its more recent investments include mitochondrial disease drug developer Mission Therapeutics, gene therapy startup SpliceBio and precision immunology company GlycoEra.
Fernando Moncada Rivera
Fernando Moncada Rivera is a reporter at Global Corporate Venturing and also host of the CVC Unplugged podcast.
